GNAI1 and glioblastoma: We have shown previously that increasing cAMP levels in glioma cells results in growth inhibition [29], suggesting that, in conjunction with the use of PDE inhibitors such as Mardepodect, raising intracellular cAMP levels in GBM cells by antagonizing Gi-linked GPCRs such as B2R could be therapeutically relevant.